A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenase–Deficient Cells in Myeloid Neoplasms

TET2 is frequently mutated in myeloid neoplasms. Genetic TET2 deficiency leads to skewed myeloid differentiation and clonal expansion, but minimal residual TET activity is critical for survival of neoplastic progenitor and stem cells. Consistent with mutual exclusivity of TET2 and neomorphic IDH1/2...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Cancer Discov
Autores principales: Guan, Yihong, Tiwari, Anand D., Phillips, James G., Hasipek, Metis, Grabowski, Dale R., Pagliuca, Simona, Gopal, Priyanka, Kerr, Cassandra M., Adema, Vera, Radivoyevitch, Tomas, Parker, Yvonne, Lindner, Daniel J., Meggendorfer, Manja, Abazeed, Mohamed, Sekeres, Mikkeal A., Mian, Omar Y., Haferlach, Torsten, Maciejewski, Jaroslaw P., Jha, Babal K.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Association for Cancer Research 2020
Materias:
Research Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7935131/
https://ncbi.nlm.nih.gov/pubmed/33681816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2643-3230.BCD-20-0173
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares